# ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu

> **NCT06824363** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **University of California, Irvine** · enrollment: 34 (estimated)

## Conditions studied

- Solid Tumor, Adult
- Malignant Solid Tumor
- Stomach Adenocarcinoma
- Esophageal Adenocarcinoma

## Interventions

- **DRUG:** Tremelimumab
- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT06824363
- **Lead sponsor:** University of California, Irvine
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2027-01
- **Final completion:** 2028-07
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2026-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06824363

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06824363, "ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06824363. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*